Proprietary AI analyst is now available

EvokAI Valuation Multiples

Discover EvokAI's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Longevity Health Holdings, Epigenomics, Brain Scientific, Strata Skin Sciences and more.

EvokAI Overview

About EvokAI

EvokAI Creative Labs Inc is a medtech artificial-intelligence-powered company. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, and contract research organizations to medical professionals, patients, and healthy individuals aiming at preventing and early detecting any kind of disease and beyond, protecting the aging genome.


Founded

2011

HQ

Canada

Employees

10

Financials (FY)

Revenue: -
EBITDA: ($17M)

EV

$1M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

EvokAI Financials

EvokAI reported last fiscal year revenue of - and negative EBITDA of ($17M).

In the same fiscal year, EvokAI generated ($17M) in EBITDA losses and had net loss of ($17M).


EvokAI P&L

In the most recent fiscal year, EvokAI reported revenue of - and EBITDA of ($17M).

EvokAI is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for EvokAI
Last FY2023202620272028
EBITDA($17M)($17M)
Net Profit($17M)($17M)
Net Debt$13K-

Financial data powered by Morningstar, Inc.

EvokAI Stock Performance

EvokAI has current market cap of $627K, and enterprise value of $1M.

Market Cap Evolution


EvokAI's stock price is $0.08.

EvokAI has an EPS (earnings per share) of $-2.25.

See more trading valuation data for EvokAI
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1M$627K0.1%---$-2.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

EvokAI Valuation Multiples

EvokAI trades at (0.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for EvokAI

EvokAI Financial Valuation Multiples

As of June 12, 2026, EvokAI has market cap of $627K and EV of $1M.

EvokAI has a P/E ratio of (0.0x).

Last FY2023202620272028
EV/EBITDA(0.1x)(0.1x)
EV/EBIT(0.6x)(0.6x)
P/E(0.0x)(0.0x)
EV/FCF(0.6x)(0.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified EvokAI Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

EvokAI Operational KPIs

EvokAI's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for EvokAI
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.2M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Longevity Health Holdings----
Epigenomics488.7x-(37.4x)-
Brain Scientific----
Strata Skin Sciences----
SensoDetect0.7x-(0.2x)-
Inhalation Sciences SWE2.5x-(0.8x)-
Work Medical Technology Group0.2x-7.1x-
Chordate Medical Holding----

This data is available for Pro users. Sign up to see all EvokAI competitors and their valuation data.

Start Free Trial

Acquisitions by EvokAI

EvokAI has acquired 2 companies to date.

Last acquisition by EvokAI was on June 1st 2023. EvokAI acquired Neurocarrier for $3M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by EvokAI

Neurocarrier
Advancience
Description
Neurocarrier is a medtech provider of neural interface components for prosthetics and implants. Based in Minneapolis, Minnesota, the company manufactures biocompatible carriers for drug delivery and electrode arrays, supplying neurosurgery centers in North America.
Advancience is a Zurich-based data science company developing game-based digital assessments for brain health diagnostics in psychiatry and neurology. Its online toolkit measures cognitive functions including attention, memory, and executive control using adaptive algorithms and reference data from 100,000 participants. Deployed in clinics across Europe, Advancience supports ADHD, dementia, and schizophrenia evaluations with automated statistical reporting.
HQ CountrySwitzerlandSwitzerland
HQ City
Basel
Basel
Deal Date1 Jun 202325 May 2022
Valuation$3M$2M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all EvokAI acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About EvokAI

When was EvokAI founded?EvokAI was founded in 2011.
Where is EvokAI headquartered?EvokAI is headquartered in Canada.
How many employees does EvokAI have?As of today, EvokAI has over 10 employees.
Who is the CEO of EvokAI?EvokAI's CEO is Alejandro Antalich.
Is EvokAI publicly listed?Yes, EvokAI is a public company listed on Toronto Stock Exchange.
What is the stock symbol of EvokAI?EvokAI trades under OKAI ticker.
When did EvokAI go public?EvokAI went public in 2023.
Who are competitors of EvokAI?EvokAI main competitors include Longevity Health Holdings, Epigenomics, Brain Scientific, Strata Skin Sciences, SensoDetect, Inhalation Sciences SWE, Work Medical Technology Group, Chordate Medical Holding, Easton Pharmaceuticals, Remedent.
What is the current market cap of EvokAI?EvokAI's current market cap is $627K.
Is EvokAI profitable?No, EvokAI is not profitable.
How many companies EvokAI has acquired to date?As of June 2026, EvokAI has acquired 2 companies.
What was the largest acquisition by EvokAI?$3M acquisition of Neurocarrier on 1st June 2023 was the largest M&A EvokAI has done to date.
What companies EvokAI acquired?EvokAI acquired Neurocarrier and Advancience.
In how many companies EvokAI has invested to date?EvokAI hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to EvokAI

Lists including EvokAI

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial